{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:25Z","timestamp":1786982725861,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40121-025-01162-x","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:41:18Z","timestamp":1748842878000},"page":"1477-1497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-7473","authenticated-orcid":false,"given":"Nurilign","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4851-1462","authenticated-orcid":false,"given":"Ru","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyneth Lourdes","family":"Bibera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-1467","authenticated-orcid":false,"given":"Olakunle","family":"Oladehin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-4973","authenticated-orcid":false,"given":"Jorge A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0004-2018","author":"AJ Loughran","year":"2019","unstructured":"Loughran AJ, Orihuela CJ, Tuomanen EI. Streptococcus pneumoniae: invasion and inflammation. Microbiol Spectr. 2019. https:\/\/doi.org\/10.1128\/microbiolspec.GPP3-0004-2018.","journal-title":"Microbiol Spectr."},{"issue":"8","key":"1162_CR2","first-page":"2410","volume":"61","author":"ME Pichichero","year":"2000","unstructured":"Pichichero ME. Acute otitis media: part II. Treatment in an era of increasing antibiotic resistance. Am Fam Physician. 2000;61(8):2410\u20136.","journal-title":"Am Fam Physician"},{"issue":"Suppl 1","key":"1162_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2019.109857","volume":"130","author":"AJ Leach","year":"2020","unstructured":"Leach AJ, Homoe P, Chidziva C, et\u00a0al. Panel 6: Otitis media and associated hearing loss among disadvantaged populations and low to middle-income countries. Int J Pediatr Otorhinolaryngol. 2020;130(Suppl 1): 109857.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"6","key":"1162_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1055\/s-2005-925523","volume":"26","author":"A Ortqvist","year":"2005","unstructured":"Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med. 2005;26(6):563\u201374.","journal-title":"Semin Respir Crit Care Med"},{"key":"1162_CR5","unstructured":"World Health Organization (WHO). Child mortality (under 5 years) 2022. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/levels-and-trends-in-child-under-5-mortality-in-2020"},{"issue":"2","key":"1162_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40121-021-00434-6","volume":"10","author":"A Gamil","year":"2021","unstructured":"Gamil A, Lalas MY, Capeding MRZ, et\u00a0al. A narrative review of pneumococcal disease in children in the Philippines. Infect Dis Ther. 2021;10(2):699\u2013718.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"1162_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2471\/BLT.07.048769","volume":"86","author":"I Rudan","year":"2008","unstructured":"Rudan I, Boschi-Pinto C, Biloglav Z, et\u00a0al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408\u201316.","journal-title":"Bull World Health Organ"},{"key":"1162_CR8","unstructured":"Department of Health - Philippines. Pneumonia still PH's top killer - health expert 2020. Available from: https:\/\/manilastandard.net\/?p=317097"},{"issue":"7","key":"1162_CR9","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl B, O\u2019Brien KL, Greenbaum A, et\u00a0al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315. Lancet Glob Health. 2018;6(7):e744\u201357.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"1162_CR10","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1097\/INF.0b013e318298dfd5","volume":"32","author":"MR Capeding","year":"2013","unstructured":"Capeding MR, Bravo L, Santos J, et\u00a0al. Prospective surveillance study of invasive pneumococcal disease among urban children in the Philippines. Pediatr Infect Dis J. 2013;32(10):e383\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"1162_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00937-20","volume":"11","author":"F Ganaie","year":"2020","unstructured":"Ganaie F, Saad JS, McGee L, et\u00a0al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. MBio. 2020;11(3): e00937-20.","journal-title":"MBio"},{"key":"1162_CR12","unstructured":"GlaxoSmithKline Biologicals s.a. Synfloryx, summary of product characteristics 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/synflorix-epar-product-information_en.pdf"},{"key":"1162_CR13","unstructured":"Monthly Index of Medical Specialities (MIMS). Synflorix\u2014Full prescribing information 2023. Available from: https:\/\/www.mims.com\/philippines\/drug\/info\/synflorix\/indications"},{"issue":"3","key":"1162_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120290","volume":"10","author":"J Jokinen","year":"2015","unstructured":"Jokinen J, Rinta-Kokko H, Siira L, et\u00a0al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children\u2014A population-based study. PLoS\u00a0One. 2015;10(3): e0120290.","journal-title":"PLoS\u00a0One"},{"key":"1162_CR15","unstructured":"Pfizer Europe MA EEIG. Prevenar, summary of product characteristics 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prevenar-13-epar-product-information_en.pdf"},{"issue":"5","key":"1162_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1473-3099(18)30734-5","volume":"19","author":"B Temple","year":"2019","unstructured":"Temple B, Toan NT, Dai VTT, et\u00a0al. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. Lancet Infect Dis. 2019;19(5):497\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"1162_CR17","unstructured":"World Health Organization (WHO). Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019. Wkly Epidemiol Rec. 2019;94(8):85\u2013103."},{"issue":"7","key":"1162_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14760584.2021.1894933","volume":"21","author":"BC Wang","year":"2022","unstructured":"Wang BC, Chaiyakunapruk N, Zhu S, et\u00a0al. A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in East and Southeast Asia (2006\u20132019). Expert Rev Vaccines. 2022;21(7):885\u201398.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"1162_CR19","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s40121-021-00538-z","volume":"10","author":"J Perdrizet","year":"2021","unstructured":"Perdrizet J, Horn EK, Nua W, et\u00a0al. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants. Infect Dis Ther. 2021;10(4):2625\u201342.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"1162_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131156","volume":"10","author":"MA Haasis","year":"2015","unstructured":"Haasis MA, Ceria JA, Kulpeng W, et\u00a0al. Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines. PLoS\u00a0One. 2015;10(7): e0131156.","journal-title":"PLoS\u00a0One"},{"key":"1162_CR21","unstructured":"Guerrero AMS, Health Technology Assessment Unit, Health Regulation Team. Reassessment of 10- versus 13-valent pneumococcal conjugate vaccines (PCV) in the Philippines. In: Department of Health - Philippines, editor. 2020."},{"key":"1162_CR22","unstructured":"Department of Science and Technology - Philippines. Call for stakeholder comments on the preliminary recommendation of the Health Technology Assessment (HTA) Council on pneumococcal conjugate vaccines for pediatric use. In: DOST, editor. 2024."},{"key":"1162_CR23","unstructured":"Health Technology Assessment Unit. Reassessment of 10- versus 13-valent pneumococcal conjugate vaccines (PCV) in the Philippines. In: Department of Health - Philippines, editor. HTA Report2020."},{"key":"1162_CR24","unstructured":"Pediatric Infectious Disease Society of the Philippines. Childhood immunization schedule 2022 2022. Available from: http:\/\/www.pidsphil.org\/home\/wp-content\/uploads\/2022\/02\/CHILDHOOD-IMMUNIZATION-SCHEDULE-2022.pdf"},{"issue":"8","key":"1162_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1080\/21645515.2021.1874219","volume":"17","author":"MR Alderson","year":"2021","unstructured":"Alderson MR, Sethna V, Newhouse LC, et\u00a0al. Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL(R)). Hum Vaccin Immunother. 2021;17(8):2670\u20137.","journal-title":"Hum Vaccin Immunother"},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.vhri.2014.04.004","volume":"3","author":"XH Zhang","year":"2014","unstructured":"Zhang XH, Nievera MC, Carlos J, et\u00a0al. Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines. Value Health Reg Issues. 2014;3:156\u201366.","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"1162_CR27","doi-asserted-by":"publisher","first-page":"2079305","DOI":"10.1080\/21645515.2022.2079305","volume":"18","author":"Y Lagoubi","year":"2022","unstructured":"Lagoubi Y, Sfar MT, Gomez JA. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia. Hum Vaccin Immunother. 2022;18(5):2079305.","journal-title":"Hum Vaccin Immunother"},{"key":"1162_CR28","unstructured":"World Health Organization (WHO). Life tables: life tables by country Philippines 2020. Available from: https:\/\/apps.who.int\/gho\/data\/view.searo.LT62150?lang=en"},{"issue":"3","key":"1162_CR29","first-page":"235","volume":"24","author":"AM Salonga","year":"2019","unstructured":"Salonga AM, Raguindin PF, Imperial MH, et\u00a0al. Neurologic outcome of Filipino children diagnosed with central nervous system infection. Neurol Asia. 2019;24(3):235\u201342.","journal-title":"Neurol Asia"},{"issue":"13","key":"1162_CR30","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.vaccine.2006.09.019","volume":"25","author":"S Madhi","year":"2007","unstructured":"Madhi S, Adrian P, Kuwanda L, et\u00a0al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25(13):2451\u20137.","journal-title":"Vaccine"},{"issue":"4","key":"1162_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","volume":"7","author":"JL Severens","year":"2004","unstructured":"Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397\u2013401.","journal-title":"Value Health"},{"key":"1162_CR32","unstructured":"Department of Health - Philippines. Philippine methods guide for health technology assessment 2020. Available from: http:\/\/bit.ly\/HTAMGPhilippines"},{"issue":"1","key":"1162_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12879-019-4108-y","volume":"19","author":"S Datta","year":"2019","unstructured":"Datta S, Pink J, Medley GF, et\u00a0al. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infect Dis. 2019;19(1):552.","journal-title":"BMC Infect Dis"},{"key":"1162_CR34","unstructured":"The World Bank Group. GDP per capita (current US$) - Philippines 2025. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=PH"},{"key":"1162_CR35","unstructured":"Philippine Statistics Authority. Registered live births in the Philippines, 2021 2022. Available from: https:\/\/psa.gov.ph\/statistics\/vital-statistics\/stat-tables\/released\/2021"},{"issue":"5","key":"1162_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125009","volume":"10","author":"H Kosai","year":"2015","unstructured":"Kosai H, Tamaki R, Saito M, et\u00a0al. Incidence and risk factors of childhood pneumonia-like episodes in Biliran Island, Philippines\u2014A community-based study. PLoS\u00a0One. 2015;10(5): e0125009.","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"1162_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.47895\/amp.v48i4.1054","volume":"48","author":"R Caro","year":"2014","unstructured":"Caro R, Llanes E, Ricalde R, et\u00a0al. Prevalence of clinically diagnosed acute otitis media (AOM) in the Philippines: a national survey with a developing country\u2019s perspective. Acta Med Philipp. 2014;48(4):30\u20134.","journal-title":"Acta Med Philipp"},{"key":"1162_CR38","unstructured":"National Health System (NHS). Hospital Episode Statistics (HES), 2013\u20132014 database 2022. Available from: available upon request"},{"issue":"9862","key":"1162_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","volume":"381","author":"AA Palmu","year":"2013","unstructured":"Palmu AA, Jokinen J, Borys D, et\u00a0al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214\u201322.","journal-title":"Lancet"},{"key":"1162_CR40","volume":"32","author":"H Smith-Vaughan","year":"2023","unstructured":"Smith-Vaughan H, Temple B, Trang Dai VT, et\u00a0al. Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trial. Lancet Reg Health West Pa. 2023;32: 100651.","journal-title":"Lancet Reg Health West Pa."},{"issue":"9546","key":"1162_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","volume":"368","author":"CG Whitney","year":"2006","unstructured":"Whitney CG, Pilishvili T, Farley MM, et\u00a0al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495\u2013502.","journal-title":"Lancet"},{"issue":"39","key":"1162_CR42","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1016\/j.vaccine.2018.08.020","volume":"36","author":"TM Kilpi","year":"2018","unstructured":"Kilpi TM, Jokinen J, Puumalainen T, et\u00a0al. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: a cluster-randomised trial. Vaccine. 2018;36(39):5891\u2013901.","journal-title":"Vaccine"},{"issue":"12","key":"1162_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/01.inf.0000148233.57296.90","volume":"23","author":"E Leibovitz","year":"2004","unstructured":"Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J. 2004;23(12):1142\u201352.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"1162_CR44","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/00006454-200211000-00007","volume":"21","author":"W Hausdorff","year":"2002","unstructured":"Hausdorff W, Yothers G, Dagan R, et\u00a0al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002;21(11):1008\u201316.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1162_CR45","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","volume":"5","author":"T Shiri","year":"2017","unstructured":"Shiri T, Datta S, Madan J, et\u00a0al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51\u20139.","journal-title":"Lancet Glob Health"},{"key":"1162_CR46","unstructured":"Department of Health - Philippines. Drug Price Reference Index, vaccine, pneumococcal conjugate multi-dose vial: Department of Health, 2021. Available from: https:\/\/caro.doh.gov.ph\/wp-content\/uploads\/2021\/09\/2021DPRI-as-of-9-17-2021.pdf."},{"key":"1162_CR47","unstructured":"World Health Organization (WHO). Revising global indicative wastage rates: a WHO initiative for better planning and forecasting of vaccine supply needs 2019. Available from: https:\/\/www.who.int\/docs\/default-source\/immunization\/tools\/revising-wastage-concept-note.pdf?sfvrsn=30e43557_4"},{"issue":"5","key":"1162_CR48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(22)00734-4","volume":"23","author":"I Adigweme","year":"2023","unstructured":"Adigweme I, Futa A, Saidy-Jah E, et\u00a0al. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in the Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial. Lancet Infect Dis. 2023;23(5):609\u201320.","journal-title":"Lancet Infect Dis"},{"key":"1162_CR49","unstructured":"The World Bank. Consumer Price Index (2010 = 100) - Philippines 2023. Available from: https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL?locations=PH"},{"issue":"26","key":"1162_CR50","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1016\/j.vaccine.2013.03.047","volume":"31","author":"W Kulpeng","year":"2013","unstructured":"Kulpeng W, Leelahavarong P, Rattanavipapong W, et\u00a0al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31(26):2839\u201347.","journal-title":"Vaccine"},{"issue":"11","key":"1162_CR51","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/14760584.2019.1688148","volume":"19","author":"J Nieto Guevara","year":"2020","unstructured":"Nieto Guevara J, Borys D, DeAntonio R, et\u00a0al. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines. 2020;19(11):1011\u201322.","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"1162_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/vaccines8020233","volume":"8","author":"AA Suwantika","year":"2020","unstructured":"Suwantika AA, Zakiyah N, Kusuma ASW, et\u00a0al. Impact of switch options on the economics of pneumococcal conjugate vaccine (PCV) introduction in Indonesia. Vaccines (Basel). 2020;8(2):233.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1162_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cmi.2019.04.026","volume":"26","author":"A Lochen","year":"2020","unstructured":"Lochen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2020;26(1):60\u201370.","journal-title":"Clin Microbiol Infect"},{"issue":"14","key":"1162_CR54","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.vaccine.2018.02.088","volume":"36","author":"AA Palmu","year":"2018","unstructured":"Palmu AA, Jokinen J, Nieminen H, et\u00a0al. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial. Vaccine. 2018;36(14):1816\u201322.","journal-title":"Vaccine"},{"issue":"1","key":"1162_CR55","doi-asserted-by":"publisher","first-page":"2013693","DOI":"10.1080\/21645515.2021.2013693","volume":"18","author":"P Izurieta","year":"2022","unstructured":"Izurieta P, Scherbakov M, Nieto Guevara J, et\u00a0al. Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media. Hum Vaccin Immunother. 2022;18(1):2013693.","journal-title":"Hum Vaccin Immunother"},{"issue":"9189","key":"1162_CR56","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0140-6736(99)00232-9","volume":"354","author":"F Shann","year":"1999","unstructured":"Shann F. Haemophilus influenzae pneumonia: type b or non-type b? Lancet. 1999;354(9189):1488\u201390.","journal-title":"Lancet"},{"key":"1162_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.15172\/pneu.2015.6\/520","volume":"6","author":"MPE Slack","year":"2015","unstructured":"Slack MPE. A review of the role of Haemophilus influenzae in community-acquired pneumonia. Pneumonia (Nathan). 2015;6:26\u201343.","journal-title":"Pneumonia (Nathan)"},{"key":"1162_CR58","volume-title":"A health economic evaluation on the long-term affordability and sustainability of pneumococcal conjugate vaccination implementation in the Philippines","author":"G Bibera","year":"2020","unstructured":"Bibera G, Varghese L, Sohn WY, et\u00a0al. A health economic evaluation on the long-term affordability and sustainability of pneumococcal conjugate vaccination implementation in the Philippines. Manila: PIDSP; 2020."},{"issue":"6","key":"1162_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001657","volume":"11","author":"M Tregnaghi","year":"2014","unstructured":"Tregnaghi M, S\u00e1ez-Llorens X, L\u00f3pez P, et\u00a0al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6): e1001657.","journal-title":"PLoS Med"},{"issue":"6","key":"1162_CR60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM200102083440602","volume":"344","author":"J Eskola","year":"2001","unstructured":"Eskola J, Kilpi T, Palmu A, et\u00a0al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403\u20139.","journal-title":"N Engl J Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01162-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:50:16Z","timestamp":1757177416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01162-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01162-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nurilign Ahmed and Jorge Gomez are employed by and hold financial equities in GSK. Olakunle Oladehin and Gyneth Lourdes Bibera were employed by and held financial equities in GSK at the time of the study. Ru Han and Edwin Rodriguez are employed by GSK. Edgardo Ortiz is a part-time medical consultant for vaccines. These authors declare no other financial and non-financial relationships and activities and no conflicts of interest. Pneumosil is a trademark of Serum Institute of India. Synflorix is a trademark owned by or licensed to GSK. Prevenar 13 is a trademark of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Ethical approval for the development of the model was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}